Peptides, Explained: The Difference Between What's Real, What's Risky, and What's Marketed

“Peptides” has become one of the busiest words in wellness. The same TikTok feed can sell you a GLP-1 for weight loss, BPC-157 for a tendon, and ipamorelin for sleep — and treat all three as if they sit on the same shelf. They don’t. One category is FDA-approved with major randomized trials behind it. One is mostly preclinical and currently barred from compounding for safety reasons. One is prescription-only, in regulatory limbo, and routinely sold in places it shouldn’t be.

Here is the honest version: peptides are not a single product class. They are a chemical category — short chains of amino acids — that includes everything from FDA-approved drugs your endocrinologist prescribes to research chemicals sold under the polite label “not for human use.” The evidence base, the legality, and the safety profile change completely depending on which peptide you’re talking about. This article sorts them into three buckets: what’s regulated, what’s compounded, and what’s research-grade.

The GLP-1 receptor agonists — semaglutide (sold as Wegovy and Ozempic) and tirzepatide (Zepbound, Mounjaro) — are peptides. They are also the most rigorously studied weight and metabolic drugs in modern medicine. This is the category where the evidence is settled.

Semaglutide is FDA-approved for type 2 diabetes (Ozempic, 2017), chronic weight management in adults with obesity or overweight plus a weight-related condition (Wegovy, 2021), and — in March 2024 — cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. The flagship weight-loss data come from the STEP trial program: in STEP 1, adults without diabetes lost an average of roughly 15% of body weight on semaglutide 2.4 mg over 68 weeks, compared with about 2.4% on placebo.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Mounjaro, 2022) and for chronic weight management (Zepbound, late 2023). The SURMOUNT program has been even more striking on weight: SURMOUNT-1 showed roughly 20% mean body weight loss on the 15 mg dose over 72 weeks. SURMOUNT-5, a head-to-head 72-week trial reported in 2025, found tirzepatide outperformed semaglutide on weight outcomes — about 31.6% of tirzepatide patients lost at least 25% of body weight, versus 16.1% on semaglutide.

These are real drugs with real trial registries, manufactured under FDA oversight, with known side-effect profiles (GI upset is most common; pancreatitis and gallbladder issues are uncommon but real). They are also peptides — they just aren’t usually labeled that way in the influencer aisle. Naya prescribes GLP-1s as part of our medical weight loss program; the relevant point here is that this is the category of peptide where the regulatory and evidence questions are answered.

This is where the wellness conversation gets murky, and where most of the social-media peptide chatter actually lives. BPC-157 (“body protection compound”) is the headliner — a synthetic 15-amino-acid peptide derived from a fragment of a stomach-protecting protein, promoted for tendon and ligament healing, gut inflammation, and general recovery. The evidence is mostly animal studies. There are no large, well-controlled human RCTs supporting BPC-157 for any indication. A 2025 preprint review and multiple peer-reviewed editorials make the same point: the mechanistic story is interesting, the human data are not there yet.

The regulatory story changed in September 2023, when the FDA placed roughly 19 peptide-related bulk drug substances — BPC-157 among them — into Category 2 of the interim 503A bulks list. Category 2 means the FDA has identified “significant safety risks” and that, under interim policy, compounding pharmacies cannot use these substances to make medications for individual patients. In plain terms: BPC-157 cannot legally be compounded by a 503A pharmacy in the U.S. while it remains in Category 2. As of early 2026, BPC-157 is still in Category 2, with a Pharmacy Compounding Advisory Committee (PCAC) review scheduled for mid-2026.

A separate group of peptides was moved off Category 2 in September 2024 — including CJC-1295, ipamorelin acetate, AOD-9604, thymosin alpha-1, and Selank — after their original nominators withdrew the nominations. That removal was procedural, not a safety endorsement. Those peptides did not move to Category 1 (the “okay to compound” list); they entered a new PCAC review process where the FDA’s own analyses, released in October and December 2024, recommended against including most of them on the bulks regulation. They remain unapproved drugs without an FDA-sanctioned pathway, and marketing them for human use without approval is illegal.

The takeaway most patients miss: “available from a peptide website” is not the same as “legal and regulated.” A peptide sold under a “research only, not for human use” disclaimer is not subject to the manufacturing standards, sterility testing, or potency verification that apply to FDA-approved drugs or to compounded medications from a licensed 503A pharmacy. Investigations have found contaminants, off-target sequences, and dosing inaccuracies in research-chemical peptides.

Sermorelin, ipamorelin, CJC-1295, and tesamorelin are growth hormone secretagogues — peptides that prompt the pituitary to release the body’s own growth hormone, rather than replacing it directly. They occupy a complicated middle ground.

Sermorelin is the cleanest case: it was FDA-approved in 1997 for pediatric growth hormone deficiency, was commercially discontinued in 2008, and remains legal to prescribe and compound under Section 503A today. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy and is the only currently marketed branded GHRH analog. Ipamorelin and CJC-1295 have no FDA-approved human drug product. After being removed from Category 2 in September 2024, both sit in a regulatory gray zone — not on the prohibited list, not on the approved list, with the FDA’s own review staff recommending against formal addition.

The marketing claim attached to this category is “anti-aging” — better sleep, lean muscle, faster recovery, fat loss. The evidence is mixed at best. The pituitary does release a pulse of growth hormone in response to these agents in lab studies; whether that translates into the body-composition and longevity outcomes the marketing implies, in healthy adults with normal growth hormone axis function, is not established by randomized trials. Growth hormone itself, when prescribed off-label for anti-aging in adults without documented deficiency, is a federal crime under the Food, Drug, and Cosmetic Act — a fact most “GH peptide” pitches don’t mention.

If these peptides are prescribed at all, it should be by a clinician who knows the regulatory status, screens for contraindications (any history of cancer is a hard pause; secretagogues raise IGF-1, which has mitogenic effects), monitors IGF-1 and metabolic labs, and uses a pharmacy that meets 503A or 503B standards. None of that describes a website checkout.

The headline events:

• September 2023: FDA moves 19 peptide-related substances, including BPC-157, into Category 2 of the interim 503A bulks list — effectively barring compounding.
• September 2024: FDA removes five substances (CJC-1295, ipamorelin acetate, AOD-9604, thymosin alpha-1, Selank) from Category 2 after the nominators withdraw. The substances do not become approved; they enter PCAC review.
• October–December 2024: PCAC reviews ipamorelin, CJC-1295, and others. FDA staff recommend against adding them to the 503A bulks regulation.
• 2025: FDA continues warning letters to pharmacies and online sellers marketing unapproved peptides for human use. BPC-157 remains in Category 2.
• 2026: A PCAC meeting is scheduled for July 23–24 to consider seven additional peptides.

The direction of travel is more enforcement, not less. “Compounded peptide” carried very different meaning in 2022 than it does in 2026.

The questions that separate careful clinics from sketchy ones are mostly the same ones you would ask about any prescription medication. Is the peptide FDA-approved for this indication, or off-label? If off-label, what is the published human evidence? Who manufactures the product — an FDA-registered facility, a licensed 503A or 503B compounding pharmacy, or a website that requires you to check a “for research purposes only” box? What’s being monitored — labs, side effects, response — and how often? What’s the exit plan if it isn’t working, or if regulatory status changes mid-course?

For Naya specifically: we prescribe GLP-1 agonists (semaglutide and tirzepatide) as part of a medically supervised weight management program, with full labs, screening, and follow-up — the bucket-1 evidence base is the reason. We don’t dispense BPC-157, ipamorelin, CJC-1295, or other compounded peptides whose regulatory status is unsettled, and we’d point to that as a feature rather than a limitation.

If you’d like to talk through whether a GLP-1 fits your situation, or want a straight answer on something a friend or influencer suggested, that’s the kind of conversation we have at Naya Wellness. Carolyn Pampalone, MSN, FNP-BC, has nearly two decades in women’s health and hormone-related care and can help you sort out what the evidence supports, what it doesn’t, and what’s currently legal to prescribe. You can talk it through at our Chatsworth or Santa Barbara clinics, or by telehealth across California.

Two California locations and statewide telehealth — click a card to view details, or call to schedule a consult.